Healthcare / Medical DevicesKOSDAQ
$4735.00
-135.00 (-2.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-2.3B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$95.0B
P/E
12.9x
↓EV/EBITDA
7.8x
↓ROE
11.1%
↑Gross Margin
48.6%
↑Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.8%
FCF CAGR
-66.2%
FCF margin
0.1%
FCF / Net income
0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $45.39B · net income $7.50B · FCF $65.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $45.39B | $45.39B | $34.23B | $27.80B | $19.84B |
| Net Income | $7.50B | $7.50B | $5.65B | $3.66B | $835.5M |
| EBITDA | $13.29B | $13.29B | $11.03B | $5.24B | $5.87B |
| EPS | 368.00 | 368.00 | 285.00 | 192.00 | 5.00 |
| Gross Margin | 48.6% | 48.6% | 48.9% | 46.9% | 44.0% |
| Operating Margin | 19.5% | 19.5% | 20.1% | 17.4% | 12.7% |
| Net Margin | 16.5% | 16.5% | 16.5% | 13.2% | 4.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.33 | 0.23 | 0.38 |
| Current Ratio | 2.18 | 2.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $65.1M | $65.1M | $-2.33B | $-2.83B | $1.68B |
| Returns | |||||
| ROE | 11.1% | 11.1% | 9.5% | 7.1% | 2.3% |
| Valuation | |||||
| P/E | 12.87 | 12.87 | 23.54 | 27.34 | 654.00 |
| EV/EBITDA | 7.81 | 7.81 | 12.94 | 20.56 | 93.38 |
| P/B | 1.43 | 1.43 | 2.24 | 1.93 | 14.97 |
| Growth & Yield | |||||
| Revenue Growth | 32.6% | 32.6% | 23.2% | 40.1% | — |
| EPS Growth | 29.1% | 29.1% | 48.4% | 3740.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
4.5%
EPS terminal req.
$420.15
Spread vs growth
24.6%
5Y implied EPS CAGR
6.7%
EPS terminal req.
$508.38
Spread vs growth
22.4%
10Y implied EPS CAGR
8.3%
EPS terminal req.
$818.76
Spread vs growth
20.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.1%
Start / end P/E
23.8x → 12.9x
EPS bridge
285.00 → 368.00
Residual
-13.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.